Table 1.
Characteristics of patients and tumors at diagnosis.
| Characteristic | value | |
|---|---|---|
| Age (ages) | ||
| Mean ± SD | 68.5 ± 8.2 | |
| Median (range) | 69.0 (40-84) | |
| tPSA at PSMA PET/CT (ng/mL) | ||
| Median (P25-P75) | 30.7 (8.8-149.5) | |
| SUVmax | ||
| Mean ± SD | 21.3 ± 19.2 | |
| Median (P25-P75) | 16.0 (7.9-25.1) | |
| Injection dose (MBq) | ||
| Mean ± SD | 141.9 ± 21.5 | |
| Median (range) | 142.1(67.0-181.3) | |
| Uptake time (minutes) | ||
| Mean ± SD | 66.617 ± 14.5 | |
| Median (range) | 62(40-98) | |
| T-stage, n (%) | ||
| T2a | 5 (8.8%) | |
| T2b | 5 (8.8%) | |
| T2c | 38 (66.7%) | |
| T3a | 2 (3.5%) | |
| T3b | 4 (7.0%) | |
| T4 | 3 (5.3%) | |
| Gleason score, n (%) | ||
| 6 | 3 (5.3%) | |
| 3+4 = 7 | 2 (3.5%) | |
| 4+3 = 7 | 8 (14.0%) | |
| 8 | 22 (38.6%) | |
| 9 | 17(29.8%) | |
| 10 | 5(8.8%) | |
| Risk-group according to D’Amico, n (%) | ||
| High | 57(100.0%) | |